TOP TEN perturbations for 39704_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39704_s_at
Selected probe(set): 206074_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39704_s_at (206074_s_at) across 6674 perturbations tested by GENEVESTIGATOR:

SDF study 4 / untreated MDA Mb231 cell sample

Relative Expression (log2-ratio):-4.4087076
Number of Samples:3 / 6
Experimental SDF study 4
MDA Mb231 cells treated with 75nM stromal derived factor (SDF; Cxcl12) for 6h.
Control untreated MDA Mb231 cell sample
Untreated MDA Mb231 cells harvested after 6h.

ovarian tumor study 14 / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):3.8432055
Number of Samples:4 / 4
Experimental ovarian tumor study 14
Human pooled cancer samples from the ovary of patients with moderate and poorly differentiated serous carcinoma of the ovary.
Control normal ovarian surface epithelial cell sample
Human epithelial cell samples from histopathological normal and non-cancerous ovary tissue from donors with non-cancerous, benign gynecological diseases.

Hep-G2 / HepaRG

Relative Expression (log2-ratio):3.707882
Number of Samples:9 / 12
Experimental Hep-G2
Human primary cancer cell line derived from the liver of a patient with hepatocellular carcinoma. Synonyms:HEP-G2; Hep G2; HEP G2; HepG2; HEPG2 Cellosaurus code:
Control HepaRG
Immortalized cancer cell line derived from female patient with hepatocellular carcinoma. Cells can be induced to differentiate into hepatocyte-like cells by exposure to DMSO. Synonyms:Hepa-RG Cellosaurus code:

T-cell activation study 4 / normal resting T-cell sample

Relative Expression (log2-ratio):3.6183395
Number of Samples:2 / 2
Experimental T-cell activation study 4
T-cell samples antiCD3 activated for 30hrs.
Control normal resting T-cell sample
T cells resting for 30h.

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)

Relative Expression (log2-ratio):-3.4994478
Number of Samples:2 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, clear cell sarcoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, clear cell sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.

stem cell differentiation study 47 (BMP-2; TGFb; 7d) / stem cell differentiation study 47 (0d)

Relative Expression (log2-ratio):-3.4415693
Number of Samples:3 / 6
Experimental stem cell differentiation study 47 (BMP-2; TGFb; 7d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml) and transforming growth factor beta (TGFb, 5 ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2, 5 ng/ml TGFb), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (0d)
Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

stem cell differentiation study 47 (BMP-2; 7d) / stem cell differentiation study 47 (0d)

Relative Expression (log2-ratio):-3.3681593
Number of Samples:3 / 6
Experimental stem cell differentiation study 47 (BMP-2; 7d)
Bone marrow-derived mesenchymal stem cell line (MSC) differentiated for 7 days in the presence of bone morphogenetic protein 2 (BMP-2, 50ng/ml). Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (PM, high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin). Subsequently PMCs were differentiated for 7 days in differentiation medium (consisting of PM with 10EXP(-6)M dexamethasone, 10 μg/ml insulin, 10EXP(-7) M rosiglitazone, 50 ng/ml BMP-2), and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).
Control stem cell differentiation study 47 (0d)
Undifferentiated bone marrow-derived mesenchymal stem cell line (MSC) without any treatment. Cells were propagated for not more than five passages in mesenchymal stem cell growth medium, at 37 °C and in a humidified atmosphere containing 7.5 % CO2. MSCs were incubated for 24 hours in proliferation medium (high glucose DMEM, 10 % FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin) and harvested. Samples are biological replicates. Normal bone marrow was obtained from 3 healthy donors (5F0138, 6F4085, 7F3458).

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary)

Relative Expression (log2-ratio):-3.2808323
Number of Samples:3 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, malignant peripheral nerve sheath tumor of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted).

expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic) / expO ovary cancer study 1 (endometrioid carcinoma; metastatic)

Relative Expression (log2-ratio):-3.2686129
Number of Samples:2 / 3
Experimental expO ovary cancer study 1 (granulosa cell tumor, malignant; metastatic)
Metastatic tumor tissue samples obtained from patients with primary granulosa cell tumor of the ovary.
Control expO ovary cancer study 1 (endometrioid carcinoma; metastatic)
Metastatic tumor tissue samples obtained from patients with primary endometrioid carcinoma of the ovary.

HCC study 9 (HBV; HCV) / normal liver tissue

Relative Expression (log2-ratio):3.255415
Number of Samples:2 / 10
Experimental HCC study 9 (HBV; HCV)
Liver tissue biopsy sample from patients with Hepatitis B and C infection related hepatocellular carcinoma (HCC) after resection.
Control normal liver tissue
Normal, non-tumor liver tissue.